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Targeting IL-34 in chronic
inflammation§
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A second ligand for colony-stimulating factor-1 receptor (CSF-1R) with distinct biologic activities had
long been implicated but not appreciated until the recent discovery of interleukin (IL)-34. IL-34 and CSF-
1 signal through this common receptor to mediate the biology of mononuclear phagocytic cells.
Aberrant macrophage activation by CSF-1 and/or IL-34 is associated with numerous diseases, and
clinical therapies targeting this pathway are being tested. Although IL-34 and CSF-1 have distinct
activities under physiologic conditions, they appear functionally redundant in various disease states.
Thus, blocking the activity of both might be necessary for maximal efficacy.Introduction
Cells of the mononuclear phagocytic lineage including mono-
cytes, macrophages, Langerhans cells, osteoclasts and microglia
are involved in tissue development, homeostasis and repair and
serve as key regulators of immune function. However, dysregula-
tion of these cells contributes to a variety of diseases including
inflammation, cancer, fibrosis and bone disease.
Colony-stimulating factor-1 (CSF-1) signaling through the CSF-
1 receptor (CSF-1R), a type III receptor tyrosine kinase, regulates
mononuclear phagocytic cell biology and has been well studied
since its discovery over three decades ago. It had long been
postulated that there was a second ligand for CSF-1R, because
the phenotypes of the CSF-1 and CSF-1R knockout mice were not
entirely complementary. Recently, interleukin (IL)-34 was identi-
fied as a potent activator of monocytes and macrophages, signal-
ing through CSF-1R with a distinct tissue distribution from CSF-1
[1]. IL-34 and CSF-1 share many functional properties; however,
notable differences suggest these two cytokines serve complemen-
tary rather than redundant roles in supporting macrophage ho-
meostasis. In this review we discuss the most recent advances in
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mune and inflammatory diseases.
Discovery of IL-34
The possibility of a second ligand for CSF-1R had been predicted by
the more severe phenotype seen in CSF-1R-deficient (CSF-1R/)
mice compared with CSF-1-deficient (CSF-1op/op) mice, which har-
bor an inactivating mutation in the csf-1 gene [2]. CFS-1op/op mice
had an osteopetrotic phenotype at birth characterized by a profound
loss of bone osteoclasts and reduction of macrophages in some
tissues that were partially restored with age. Microglia numbers
were only modestly reduced and Langerhans cell development in
the skin appeared relatively normal. By contrast, CSF-1R/ mice
were severely depleted of macrophages and lacked Langerhans cells,
microglia and osteoclasts throughout their lifespan. Therefore, it
appeared that some activities of CSF-1R were mediated indepen-
dently of CSF-1, possibly through a second ligand.
IL-34 was identified by screening a comprehensive human
protein library containing 3400 secreted and extracellular do-
main proteins in a human monocyte viability assay [1]. C16orf77,
a hypothetical protein in the National Institutes of Health’s Mam-
malian Gene Collection database, supported the survival of hu-
man peripheral blood monocytes and was designated as IL-34. The
activity of IL-34 appeared specific to the monocyte and macro-
phage lineage because it did not affect 28 other cell types tested
in a variety of assays. IL-34 lacked appreciable sequence similarity
to every other cytokine or protein. The receptor for IL-34 wass. Published by Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.drudis.2014.05.016















Nidentified by screening a library of extracellular domains of trans-
membrane proteins for the ability to block IL-34 activity in the
monocyte viability screen. The identified receptor was CSF-1R.
Further functional studies confirmed the specific activity of IL-34
through CSF-1R on monocyte-lineage cells.
IL-34 biology
In many aspects IL-34 functions similarly to CSF-1, however some
differences between the two cytokines have been identified. IL-34
supports the growth and survival of primary human monocytes and
promotes the formation of macrophage colonies from human bone
marrow equivalently to CSF-1 and was found to be able to substitute
for CSF-1 in receptor activator of nuclear factor kappa-B ligand
(RANKL)-induced osteoclastogenesis [3,4]. In vivo, the mouse IL-
34 gene expressed transgenically under the control of the mouse
CSF-1 promoter was able to rescue the defects of the CSF-1op/opmice
[5]. Similar to CSF-1, IL-34 stimulation of CSF-1R leads to phos-
phorylation of extracellular signal-regulated kinase (ERK) 1/2 in
human monocytes [1]. However, IL-34 binds to CSF-1R with higher
affinity than CSF-1 and was found to produce a stronger but more
transient tyrosine phosphorylation of CSF-1R and downstream
mediators, suggesting the two cytokines differ somewhat in signal-
ing activity [6]. Studies on human monocytes determined that 68%
of the IL-34- or CSF-1-induced gene expression changes were similar
for the two stimuli, whereas only 32% differed [7]. In general, IL-34
induced transcriptional changes of a lesser magnitude than CSF-1.
The most notable difference between IL-34 and CSF-1 is their
expression patterns in embryonic and adult tissues. CSF-1 has
relatively broad expression whereas IL-34 expression is more re-
stricted. Strikingly, IL-34 mRNA was strongly expressed in the
embryonic brain before the appearance of CSF-1 mRNA expression,
and IL-34 was expressed more strongly in most areas of the postnatal
and adult brain in largely nonoverlapping regions to CSF-1 [5,8].
The expression data suggest that IL-34 and CSF-1 serve complimen-
tary nonredundant roles in the developing central nervous system.
To identify IL34-specific effects two groups produced IL-34-
deficient reporter mice. Mice deficient in IL-34 displayed a marked
reduction of Langerhans cells and a decrease in microglia, whereas
monocytes, tissue macrophages and dendritic cells were largely
unaffected [9,10]. IL-34 was expressed primarily by keratinocytes
in the epidermis and neurons in the brain. IL-34 was essential for
embryonic development of Langerhans cells and for their homeo-
stasis in the adult in the steady state. Under conditions of inflam-
mation in the skin, IL-34 was not required for the recruitment of
blood-borne precursors and their differentiation into Langerhans
cells but was crucial for their maintenance after inflammation was
resolved. Reductions of Langerhans cells in the IL-34-deficient
mice resulted in reduced sensitivity to chemical hapten- and
Candida-albicans-mediated contact hypersensitivity [10]. IL-34
was found to be essential for microglia homeostasis in specific
areas of the adult brain but was not required for embryonic
development of microglia [9]. The reduction of microglia in the
IL-34-deficient mice did not cause a substantially altered pheno-
type in the central nervous system under steady-state conditions
but did negatively affect the survival of mice infected intracrani-
ally with an attenuated strain of West Nile virus [10].
In addition to expression in skin and brain, IL-34 transcripts are
also detected in various tissues including the spleen, kidney andtestes. IL-34 is abundantly expressed in human spleen and studies
in CSF-1-deficient mice suggest that IL-34 plays a pivotal part in
maintaining the splenic reservoir of osteoclast precursor cells [11].
A gene expression study of lymph node stromal cells found IL-34
expressed by fibroblast reticular cells, suggesting IL-34 could regu-
late myeloid cell function in lymph node immune responses [12].
A group studying the role of follicular dendritic cells (FDCs) in
controlling B cell fate in germinal centers found that a mouse FDC
line produced IL-34 that promoted the differentiation of a partic-
ular type of mononuclear phagocytic cell designated as a follicular
dendritic cell-induced monocytic cell (FDMC) that was capable of
stimulating activated B cell proliferation [13]. The FDC line pro-
duced CSF-1 in addition to IL-34; however, IL-34 but not CSF-1 was
reported to be responsible for FDC-mediated generation of the
FDMCs. Additional studies in IL-34-deficient mice are needed to
confirm IL-34 specificity in promoting B cell follicle-associated
macrophage differentiation and to determine the role of FDMCs in
germinal center reactions.
It was observed that IL-34 and CSF-1R showed differential
expression in the brain, suggesting that IL-34 could signal via
an alternative receptor. This led to the discovery that IL-34 also
interacts with receptor-type protein-tyrosine phosphatase z (PTP-
z), a cell surface chondroitin sulfate (CS) proteoglycan [14]. PTP-z is
primarily expressed on neural progenitors and glial cells and
possesses multiple ligands. IL-34 binding inhibits the constitutive
phosphatase activity of PTP-z leading to increased tyrosine phos-
phorylation of downstream targets. To date, no CSF-1R-indepen-
dent functions of IL-34 have been identified. It is possible that PTP-
z and CSF-1R cooperate to mediate IL-34 activity, although further
studies are needed to identify CSF-1R-dependent or -independent
IL-34 signaling through PTP-z.
CSF-1R expression is restricted primarily to cells of the mono-
nuclear phagocytic lineage. This includes macrophage precursors
in the bone marrow, monocytes, osteoclasts and tissue macro-
phages including Kupffer cells in the liver and microglia in the
brain. In non-hematopoietic cells CSF-1R is expressed on tropho-
blasts. Different groups have also reported CSF-1R expression on
epithelial cells of colonic crypts, on subsets of neurons and on
renal proximal tubule cells. However, not all studies support these
observations and the expression of CSF-1R on some non-mono-
cyte lineage cells remains controversial: discussed in [15].
Structural basis of CSF-1R activation by IL-34
The discovery that IL-34 and CSF-1 could activate CSF-1R raised
the question of how these two disparate cytokines structurally
engaged CSF-1R. IL-34 and CSF-1 were shown to compete for
binding to CSF-1R, and anti-CSF-1R monoclonal antibodies
(mAbs) were identified that could block CSF-1 but not IL-34
suggesting the two cytokines share overlapping but distinct bind-
ing sites [5,6]. Although IL-34 shares no appreciable sequence
similarity with any other protein it was proposed by fold recogni-
tion to be a four-helix bundle cytokine belonging to the same
family as CSF-1 [16]. Recently, the crystallographic structures of
truncated versions of human and mouse IL-34 were solved and IL-
34 was confirmed to be a four-helix bundle cytokine, albeit with
some unique features [17,18]. IL-34 forms a noncovalently linked
dimer whereas CSF-1 contains an intersubunit disulfide bond.
The structure of the IL-34–CSF-1R complex shows a similarwww.drugdiscoverytoday.com 1213













Nligand–receptor assembly to that of CSF-1–CSF-1R. Dimeric IL-34
and CSF-1 bind the same general region of CSF-1R by interacting
with overlapping but distinct epitopes on CSF-1R [17–19].
Preclinical studies
Benefits of blocking the CSF-1R pathway have been shown in
numerous animal models of chronic disease. CSF-1-deficient mice
are protected from arthritis, bone loss, nephritis, cutaneous lupus
and lung fibrosis, and these disorders are also reduced in the
setting of CSF-1 or CSF-1R blockade, reviewed in [20,21]. Results
in inflammatory bowel disease models were mixed depending on
the model used.
Although numerous animal studies demonstrate the benefit of
blocking the CSF-1R pathway in inflammation not all studies sup-
port this. A study using a particular anti-CSF-1R antibody found no
inhibitory effect in acute inflammation models, discussed in [20,21].
This is in contrast to results reported in a second study using similar
models but a different anti-CSF-1R antibody. This discrepancy could
be explained by different modes of action of these two antibodies
caused by either differences in epitope binding, and thus differential
CSF-1 versus IL-34 blockade, or differences in Fc effector function.
Additionally, the models studied were acute inflammatory models,
and the relevance of the CSF-1R pathway might differ between acute
and chronic disease models. Targeting the CSF-1R pathway in
chronic inflammatory disease models has been shown to be effica-
cious [20]. More-recent studies demonstrated efficacy of CSF-1R
inhibition in mouse models of cancer. A blocking anti-CSF-1R
mAb reduced anti-inflammatory tumor-associated macrophages
resulting in reduced tumor growth and prolonged survival [22].
In a glioblastoma model, small molecule inhibition of CSF-1R
resulted in tumor growth inhibition and polarizing tumor-associat-
ed macrophage to a proinflammatory phenotype [23]. Thus,
depending on the disease context, and probably the subsets of
macrophage involved, CSF-1R pathway inhibition could have ben-
eficial anti-inflammatory or proinflammatory effects.
IL-34 pathology in rheumatoid arthritis and other
inflammatory diseases
Rheumatoid arthritis (RA) is a chronic autoimmune disorder of the
joints characterized by synovial inflammation and hyperplasia
leading to progressive cartilage and bone destruction. Activated
macrophages are the predominant infiltrating cell type in the
inflamed synovium and promote inflammation through produc-
tion of inflammatory cytokines such as tumor necrosis factor
(TNF)a and IL-6 [24]. Factors from the inflamed synovium drive
the differentiation of monocytic lineage cells to osteoclasts, which
mediate bone destruction. The CSF-1R pathway is thought to play
a predominant part by promoting the differentiation and survival
of monocytes and macrophages and osteoclasts. In support of this,
activation of CSF-1R has been detected in RA synovium and CSF-1
expression is upregulated in RA [25].
To understand the role of IL-34 in RA several groups have looked
at the expression of IL-34 in tissue and blood from RA patients.
Immunohistochemistry studies demonstrated that IL-34 is in-
creased in RA synovium compared with osteoarthritis and healthy
controls [26,27]. Chemel et al. reported a positive association
between synovial IL-34 expression levels and synovitis severity
[26]. Several groups also reported elevated levels of IL-34 in RA1214 www.drugdiscoverytoday.comblood and synovial fluid [26–29]. Some caution is needed in
interpreting the IL-34 ELISA results because it is not clear if all
groups used methods to eliminate the interference of rheumatoid
factor (RF). Moon et al. did use methods to block RF interference
and detected elevated levels of IL-34 in RA serum and synovial
fluid and found an association between IL-34 levels and RF and
anticyclic citrullinated peptide (CCP) antibody titers [28].
Functionally, isolated RA-derived fibroblast-like synovial cells
and osteoblasts were found to produce IL-34 in response to TNFa
[27,30]. As discussed above, IL-34 can promote osteoclastogenesis in
combination with RANKL and induce bone destruction [3,4]. IL-34
was also shown capable of inducing proinflammatory cytokines and
chemokines such as IL-6, IL-8 and chemokine (C-C motif) ligand
(CCL) 2 in human whole blood [31]. Together the data suggest that
IL-34 is involved in RA pathogenesis. Given that IL-34 and CSF-1 are
simultaneously expressed in RA synovium it will probably be nec-
essary to block the activity of both to produce a therapeutic benefit.
To test the effect of targeting the CSF-1R pathway in RA, we
determined the effect of blocking CSF-1R in RA synovial explants
[32]. Synovial biopsy samples were obtained by arthroscopy from
sites with active inflammation and cultured without dissociation ex
vivo. This system maintains the synovial architecture and cell–cell
contacts and therefore reflects more closely the in vivo joint envi-
ronment. Intact synovial biopsy samples continue to produce cyto-
kines and chemokines without the addition of exogenous stimulus.
Treatment with an anti-CSF-1R antibody that blocks IL-34 and CSF-
1 signaling significantly reduced IL-6 levels compared with samples
treated with an isotype control antibody. These results suggest that
targeting the CSF-1R pathway will have clinical benefit in RA.
In addition to RA, targeting the CSF-1R pathway could have
clinical benefit in other inflammatory diseases. IL-34 was found
to be overexpressed in inflamed salivary glands of patients with
Sjogren’s syndrome (SS), a chronic immune disorder typically af-
fecting exocrine glands [33]. Macrophages are recognized as an
important component of SS lesions with increased levels of macro-
phages appearing in severe lesions [34]. IL-34 expression was associ-
ated with increased expression of TNFa, IL-1b and IL-17, suggesting
that IL-34 could regulate monocytes and/or macrophages involved
in the pathogenesis of salivary gland inflammation [33].
Intriguingly, a study aimed at identifying shared inflammatory
mechanisms of lupus identified IL-34 among a limited number of
cytokines and chemokines that were upregulated in kidneys of three
different mouse models of lupus nephritis (LN) [35]. LN is associated
with inflammation caused by deposition of immune complexes in
the kidney. Macrophages are activated by these immune complexes
through Fc receptors and contribute to the chronic renal inflamma-
tion and tissue damage associated with nephritis. CSF-1 is also
upregulated in blood and urine of patients with LN [36]. The
presence of IL-34, CSF-1 and activated macrophages suggest that
targeting the CSF-1R pathway in LN might provide clinical benefit.
Strategies for blocking CSF-1R pathway activity
There are several strategies for inhibiting CSF-1R pathway activity
(Fig. 1). CSF-1R is part of a family of receptor tyrosine kinases with
intracellular domains that are very closely related. Small molecules
inhibiting the kinase activity of CSF-1R have been developed and
are being tested in the clinic. These inhibitors range from being
highly selective for CSF-1R to possessing dual activity to related
Drug Discovery Today  Volume 19, Number 8 August 2014 REVIEWS
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FIGURE 1
Strategies to block colony-stimulating factor-1 receptor (CSF-1R) activation. CSF-1R is a receptor tyrosine kinase that is activated by interleukin (IL)-34 or CSF-1.
CSF-1R signaling can be blocked by small molecule inhibitors targeting the kinase domain, by neutralizing antibodies targeting either or both IL-34 and CSF-1 or















Nkinases such as v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog (KIT) or fms-related tyrosine kinase 3 (FLT3)
[37]. Antibodies against the receptor that block binding of IL-34
and CSF-1 or block the dimerization of the receptor have also been
developed and are in early clinical testing. Dual blockade of both
cytokines could also be achieved through bi-specific antibodies
directed against the ligands or a CSF-1 receptor-trap, although
neither of these is reported to be in the clinic. Blockade of either
cytokine alone could be achieved through anticytokine antibodies
or, because the two ligands interact with unique epitopes on the
CSF-1R, antibodies directed at the CSF-1R with selective blockingTABLE 1
Clinical trials targeting the colony-stimulating factor-1 receptor (CS
Target Molecule Drug type Comp
CSF-1 MCS110 Antibody Novart
CSF-1 PD0360324 Antibody Pfizer 
CSF-1R AMG820 Antibody Amgen
CSF-1R ARRY382 Small molecule Array 
CSF-1R FPA008 Antibody Five Pr
CSF-1R IMCCS4 Antibody ImClon
CSF-1R JNJ40346527 Small molecule Johnso
CSF-1R PLX5622 Small molecule Plexxik
CSF-1R RG7155 Antibody Roche
CSF-1R/KIT/FLT3 PLX3397 Small molecule Plexxikactivity could be developed. Pfizer has tested an anti-CSF-1 mAb in
early clinical trials and in non-human primates. In non-human
primates the antibody resulted in selective reduction of CD16+
peripheral monocytes and a loss of Kupffer cells in the liver [38].
The reduction of Kupffer cells was associated with in an increase in
serum enzymes with no signs of hepatic or skeletal muscle injury.
The rise in serum enzymes was attributed to reduced clearance
caused by decreased Kupffer cell numbers and not as a result of
hepatic or skeletal injury. This conclusion was supported by addi-
tional studies in rats where treatment with clodronate liposomes to
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Nwithout evidence of tissue injury. In addition, CSF-1-deficient mice,
which have reduced levels of Kupffer cells, were found to have
higher levels of serum enzymes compared with wild-type litter-
mates. In humans the anti-CSF-1 mAb also specifically reduced
CD16+ peripheral blood monocytes [39]. CD16+ monocytes are
considered to be inflammatory and are specifically upregulated in
many inflammatory conditions including in RA [40]. Pfizer has
completed a Phase I clinical trial in RA but has not reported the
data yet. Several other compounds targeting the CSF-1R pathway are
in the clinic for autoimmune diseases or cancer (Table 1).
Concluding remarks
CSF-1 and CSF-1R involvement in disease pathology and their
potential as therapeutic targets have been well studied for years.1216 www.drugdiscoverytoday.comThe discovery of IL-34 has added a new layer of complexity to this
pathway but has also provided answers to outstanding questions.
In disease settings where IL-34, CSF-1 and CSF-1R are all present,
such as the inflamed synovium in RA, it will probably be necessary
to inhibit the activity of both ligands to achieve efficacy. More
studies are needed to understand the contribution of IL-34 to
other diseases where macrophages are implicated in the patholo-
gy (such as fibrosis and inflammatory bowel disease) and to
identify new opportunities for targeting this new cytokine for
clinical benefit.
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